- Home
- MCN vs UNCY Comparison
MCN vs UNCY Comparison
Compare MCN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCN | UNCY |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | Canada | United States |
| Employees | N/A | 22 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 138.3M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCN | UNCY |
|---|---|---|
| Price | $5.64 | $5.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 48.7K | ★ 832.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.46 | $3.72 |
| 52 Week High | $6.39 | $8.74 |
Technical Indicators
Market Signals| Indicator | MCN | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 42.46 |
| Support Level | N/A | $4.81 |
| Resistance Level | $5.69 | $5.39 |
| Average True Range (ATR) | 0.05 | 0.31 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 26.67 | 29.31 |
Price Performance
Historical ComparisonAbout MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.